Jay S. Duker - 09 Feb 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
President and CEO, Director
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
09 Feb 2024
Net transactions value
-$101,750
Form type
4
Filing time
13 Feb 2024, 17:37:59 UTC
Previous filing
09 Jan 2024
Next filing
22 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +7,000 +16% $0.000000 50,486 09 Feb 2024 Direct
transaction EYPT Common Stock Options Exercise $0 +4,967 +9.8% $0.000000 55,453 09 Feb 2024 Direct
transaction EYPT Common Stock Tax liability $59,760 -2,075 -3.7% $28.80 53,378 09 Feb 2024 Direct F1
transaction EYPT Common Stock Tax liability $41,990 -1,458 -2.7% $28.80 51,920 09 Feb 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -4,967 -100% $0.000000* 0 09 Feb 2024 Common Stock 4,967 $0.000000 Direct F2
transaction EYPT Restricted Stock Units Options Exercise $0 -7,000 -50% $0.000000 7,000 09 Feb 2024 Common Stock 7,000 $0.000000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
F2 The restricted stock units will vest in three ratable annual installments beginning February 9, 2022.
F3 The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.